Well at the end of the day isn't that what investors want to...

Well at the end of the day isn't that what investors want to really hear about to consider investing in such an underperforming stock to date- the share price and why it is so low? That's why I thought it was a good presentation because Gary addresses the issue and explains the reason behind the Karst Peak fund sell-down after the 2.2 cent raise. He also highlights the opportunity for the company in the next 12 months and - in his opinion - how there will be an opportunity for SP appreciation after full recruitment of the myelofibrosis trial with results anticipated by the end of the year. I assume that's why he mentioned the selling orders would be flushed out soon. Not sure if that's appropriate or not but he's there to raise interest in and profile of the company.